Replimune (REPL) Depreciation & Amortization (CF) (2017 - 2025)
Replimune's (REPL) quarterly Depreciation & Amortization (CF) came in at $800000.0 in Q4 2025, down 20.0% year-on-year from $1.0 million in Q4 2024, and little changed quarter-over-quarter from $800000.0 in Q3 2025.
Replimune (REPL) Depreciation & Amortization (CF) (2017 - 2025) Analysis & Trends
Replimune has disclosed Depreciation & Amortization (CF) across 9 years of filings, most recently posting $800000.0 for Q4 2025.
- Depreciation & Amortization (CF) for Q4 2025 came in at $800000.0, down 20.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $3.3 million (down 0.91% YoY), and the FY2025 annual result was $3.5 million, up 31.9% from the prior year.
- Depreciation & Amortization (CF) came in at $800000.0 for Q4 2025 at Replimune, roughly flat from $800000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.0 million in Q4 2024 to a low of $481000.0 in Q1 2023.
- The 5-year median for Depreciation & Amortization (CF) is $691000.0 (2022), against an average of $681550.0.
- Across the five-year window, Depreciation & Amortization (CF) jumped 56.31% in 2021 and decreased 20.0% in 2025, its largest moves.
- Replimune's Depreciation & Amortization (CF) stood at $548000.0 in 2021, then gained by 24.45% to $682000.0 in 2022, then gained by 2.64% to $700000.0 in 2023, then surged by 42.86% to $1.0 million in 2024, then retreated by 20.0% to $800000.0 in 2025.
- The last three Depreciation & Amortization (CF) figures came in at $800000.0 (Q4 2025), $800000.0 (Q3 2025), and $873000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 429,663.65 |
| 10 | Replimune | 780.01 Mn | 510.88 Mn | - | 800,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 800,000.00 |
| Dec 31, 2025 | 800,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 873,000.00 |
| Jun 30, 2025 | 873,000.00 |
| Mar 31, 2025 | 802,000.00 |
| Mar 31, 2025 | 802,000.00 |
| Dec 31, 2024 | 1.00 Mn |
| Dec 31, 2024 | 1.00 Mn |
| Sep 30, 2024 | 900,000.00 |
| Sep 30, 2024 | 900,000.00 |
| Jun 30, 2024 | 700,000.00 |
| Jun 30, 2024 | 700,000.00 |
| Mar 31, 2024 | 705,000.00 |
| Mar 31, 2024 | 705,000.00 |
| Dec 31, 2023 | 700,000.00 |
| Dec 31, 2023 | 700,000.00 |
| Sep 30, 2023 | 700,000.00 |
| Sep 30, 2023 | 700,000.00 |